North American Nuclear Medicine/Radiopharmaceuticals Market worth $2.98 Billion

North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020

(EMAILWIRE.COM, September 15, 2019 ) The report "North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020", analyzes and studies the major market drivers, restraints/challenges, and opportunities.

Get PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=1108

The radiopharmaceuticals market, by type is broadly classified into two segments, namely, diagnostic and therapeutic radioisotopes. Radioisotopes in the diagnostic market are further categorized as SPECT and PET; while the therapeutic market is classified into beta emitters, brachytherapy isotopes, and alpha emitters. In 2015, the diagnostic segment is expected to account for the largest share of the North American nuclear medicine market, with the SPECT segment likely to account for the largest share of the diagnostic market. While, beta emitters is expected to account for the largest share of the therapeutic market in 2015.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=1108

The North American radiopharmaceuticals market, based on application is segmented into SPECT, PET, and therapeutic applications. The SPECT applications is further segmented into Cardiology, Lymphoma

Thyroid, Neurology, and other SPECT applications, while the PET application is segmented into Oncology, Cardiology, Neurology, and other PET applications. The therapeutic application is classified into Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, and other therapeutic applications. In 2015, the cardiology application is expected to account for the largest share of North American radiopharmaceuticals market for SPECT applications. The PET market is likely to be dominated by oncology applications and the therapeutic market is likely to be dominated by thyroid applications.